Shanghai Yizhong Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000050F4
CNY
54.30
0.3 (0.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
82.82
89.28
71.03
3.73
47.69
53.22
68.70
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
82.82
89.28
71.03
3.73
47.69
53.22
68.70
Raw Material Cost
12.70
15.01
13.51
4.39
4.27
2.97
3.84
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.11
0.33
0.27
Selling and Distribution Expenses
39.96
35.30
35.06
23.71
40.88
38.70
33.29
Other Expenses
2.57
1.95
0.92
1.19
0.99
0.94
0.53
Total Expenditure (Excl Depreciation)
78.40
69.76
57.82
39.95
55.15
51.40
42.73
Operating Profit (PBDIT) excl Other Income
4.4
19.5
13.200000000000001
-36.2
-7.5
1.7999999999999998
26
Other Income
4.21
5.56
2.48
39.23
6.97
3.86
7.75
Operating Profit (PBDIT)
8.26
27.93
18.76
6.10
2.35
8.26
36.24
Interest
0.00
0.00
0.00
0.00
0.11
0.33
0.27
Exceptional Items
0.90
0.03
0.01
6.89
-0.70
0.37
0.33
Gross Profit (PBDT)
70.12
74.27
57.52
-0.66
43.42
50.25
64.87
Depreciation
0.00
3.28
3.28
3.09
3.09
2.84
2.84
Profit Before Tax
9.16
24.68
15.49
-33.28
-0.84
5.47
33.47
Tax
-3.50
0.86
1.30
-5.59
-1.00
0.14
4.29
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
12.65
23.82
14.19
-27.69
0.16
5.33
29.18
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
12.65
23.82
14.19
-27.69
0.16
5.33
29.18
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
12.65
23.82
14.19
-27.69
0.16
5.33
29.18
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
1,460.91
1,447.37
1,422.68
1,405.02
1,437.18
1,460.07
1,498.91
Earnings per share (EPS)
0.06
0.12
0.07
-0.13
0.0
0.03
0.14
Diluted Earnings per share
0.06
0.12
0.07
-0.13
0.0
0.03
0.14
Operating Profit Margin (Excl OI)
4.89%
21.38%
18.3%
-971.53%
-16.16%
2.93%
37.34%
Gross Profit Margin
11.06%
31.31%
26.42%
-809.78%
4.72%
15.61%
52.85%
PAT Margin
15.28%
26.68%
19.97%
-742.77%
0.34%
10.02%
42.47%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Sep 2025 is -7.28% vs 25.77% in Jun 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is -46.64% vs 67.61% in Jun 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -81.70% vs 37.42% in Jun 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of Shanghai Yizhong Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
82.82
0
82.82
Other Operating Income
0.00
0.00
0.00
Total Operating income
82.82
0
82.82
Raw Material Cost
12.70
0
12.70
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
39.96
0
39.96
Other Expenses
2.57
0.00
2.57
Total Expenditure (Excl Depreciation)
78.40
0
78.40
Operating Profit (PBDIT) excl Other Income
4.42
0.00
4.42
Other Income
4.21
0
4.21
Operating Profit (PBDIT)
8.26
0
8.26
Interest
0.00
0
0.00
Exceptional Items
0.90
0
0.90
Gross Profit (PBDT)
70.12
0
70.12
Depreciation
0.00
0
0.00
Profit Before Tax
9.16
0
9.16
Tax
-3.50
0
-3.50
Provisions and contingencies
0
0
0.00
Profit After Tax
12.65
0
12.65
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
12.65
0
12.65
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
12.65
0
12.65
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
1,460.91
0
1,460.91
Earnings per share (EPS)
0.06
0
0.06
Diluted Earnings per share
0.06
0
0.06
Operating Profit Margin (Excl OI)
4.89%
0%
0.00
4.89%
Gross Profit Margin
11.06%
0%
0.00
11.06%
PAT Margin
15.28%
0%
0.00
15.28%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 8.28 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -7.28% vs 25.77% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 73.58% vs -39.47% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 1.27 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -46.64% vs 67.61% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 6,250.00% vs -99.25% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 0.41 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -81.70% vs 37.42% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 189.13% vs -117.49% in Sep 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 4.89%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024